Madrigal Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resme…
Biotechnology
US, West Conshohocken [HQ]

Cash Flow Statements

15 Sheets · Starting from 2023
In Million USD. Margins, Growth Rates In %
Metric 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Operating Activities
Operating Cash Flow (OCF)
-26.00 -38.00 -47.00 -54.00 -77.00 -78.00 -71.00 -17.00 -22.00 -25.00 -41.00 -157.00 -183.00 -224.00 -324.00
Operating Cash (Net)
-26.00 -38.00 -47.00 -54.00 -77.00 -78.00 -71.00 -17.00 -22.00 -25.00 -41.00 -157.00 -183.00 -224.00 -324.00
Accounts Receivable
- - - - - - - - - - - - - - 7.00 - - - - - - - - - - - - - -
Accounts Payable
- - -2.00 1.00 2.00 - - -3.00 -1.00 - - - - - - -1.00 - - 20.00 2.00 4.00
Working Capital
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Investing Activities
Used Cash (Net)
21.00 -19.00 9.00 -9.00 -24.00 -8.00 20.00 21.00 -22.00 -380.00 30.00 159.00 -5.00 206.00 -502.00
Capital Expenditure
- - - - - - - - - - - - - - - - - - - - - - - - - - - - -1.00
Purchases of Investments
-39.00 -36.00 -50.00 -50.00 -114.00 -93.00 -117.00 -10.00 -70.00 -614.00 -619.00 -329.00 -394.00 -143.00 -834.00
Sale/Maturity of Investment
60.00 17.00 60.00 40.00 90.00 85.00 137.00 26.00 48.00 234.00 650.00 489.00 389.00 350.00 333.00
Property, Plant, Equipment (P&PE)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - -1.00
Acquisitions (Net)
- - - - - - - - - - - - - - 5.00 - - -3.00 3.00 1.00 - - - - -5.00
Other Investing Activities
- - - - - - - - - - - - - - - - - - 3.00 -3.00 -1.00 - - - - 5.00
Financing Activities
Used Cash (Net)
-2.00 -45.00 -36.00 -115.00 -69.00 -85.00 -40.00 -14.00 -173.00 -314.00 - - -5.00 -171.00 -313.00 -595.00
Debt Repayment
-2.00 -1.00 - - -4.00 -2.00 -9.00 -9.00 -8.00 - - - - - - - - - - -49.00 -64.00
Dividends Paid
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Common Stock
- - - - - - 119 - - - - - - - - - - - - - - - - - - - - - -
Other Financing Activities
-2.00 15.00 29.00 - - 13.00 - - - - 8.00 - - 2.00 - - - - 1.00 107.00 - -
Cash Balances
Begin of Period
52.00 44.00 31.00 30.00 81.00 48.00 46.00 - - 19.00 148.00 57.00 46.00 54.00 36.00 331.00
End of Period
44.00 31.00 30.00 81.00 48.00 46.00 34.00 19.00 148.00 57.00 46.00 54.00 36.00 331.00 99.00
Change
-7.00 -12.00 -1.00 51.00 -33.00 -2.00 -11.00 18.00 129.00 -91.00 -10.00 7.00 -17.00 295.00 -231.00
Non-Cash Balances
Depreciation and Amortization
2.00 1.00 1.00 - - - - - - - - - - - - - - - - - - - - - - - -
Stock Based Compensation
4.00 4.00 3.00 3.00 6.00 7.00 4.00 8.00 3.00 - - 22.00 20.00 26.00 31.00 49.00
Other
- - - - - - - - 6.00 - - 3.00 1.00 2.00 13.00 24.00 21.00 7.00 - - 6.00
Highlighted metrics
Free Cash Flow (FCF)
-27.00 -38.00 -47.00 -54.00 -78.00 -79.00 -71.00 -17.00 -22.00 -25.00 -41.00 -157.00 -184.00 -225.00 -325.00
Cash Conversion Cycle (CCC)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Invested Capital
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Other Operating Inflows/Outflows
End of MDGL's Analysis
CIK: 1157601 CUSIP: 558868105 ISIN: US5588681057 LEI: - UEI: -
Secondary Listings
MDGL has no secondary listings inside our databases.